Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types.
Chen HC, Mueller N, Stott K, Kapeni C, Rivers E, Sauer CM, Beke F, Walsh SJ, Ashman N, O'Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjoedt MO, Skjødt K, de la Roche M, de la Roche M.
Chen HC, et al. Among authors: richardson se.
EMBO Mol Med. 2024 Nov;16(11):3026. doi: 10.1038/s44321-024-00139-6.
EMBO Mol Med. 2024.
PMID: 39322863
Free PMC article.